- Home
- CPRI vs DNLI Comparison
CPRI vs DNLI Comparison
Compare CPRI & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRI
- DNLI
- Stock Information
- Founded
- CPRI 1981
- DNLI 2013
- Country
- CPRI United Kingdom
- DNLI United States
- Employees
- CPRI N/A
- DNLI N/A
- Industry
- CPRI Apparel
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CPRI Consumer Discretionary
- DNLI Health Care
- Exchange
- CPRI Nasdaq
- DNLI Nasdaq
- Market Cap
- CPRI 2.2B
- DNLI 2.1B
- IPO Year
- CPRI 2011
- DNLI 2017
- Fundamental
- Price
- CPRI $19.58
- DNLI $14.31
- Analyst Decision
- CPRI Buy
- DNLI Strong Buy
- Analyst Count
- CPRI 11
- DNLI 15
- Target Price
- CPRI $21.91
- DNLI $33.85
- AVG Volume (30 Days)
- CPRI 3.2M
- DNLI 1.5M
- Earning Date
- CPRI 08-07-2025
- DNLI 08-04-2025
- Dividend Yield
- CPRI N/A
- DNLI N/A
- EPS Growth
- CPRI N/A
- DNLI N/A
- EPS
- CPRI N/A
- DNLI N/A
- Revenue
- CPRI $4,442,000,000.00
- DNLI N/A
- Revenue This Year
- CPRI N/A
- DNLI N/A
- Revenue Next Year
- CPRI $4.53
- DNLI $323.34
- P/E Ratio
- CPRI N/A
- DNLI N/A
- Revenue Growth
- CPRI N/A
- DNLI N/A
- 52 Week Low
- CPRI $11.86
- DNLI $10.57
- 52 Week High
- CPRI $43.34
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- CPRI 61.08
- DNLI 49.46
- Support Level
- CPRI $19.02
- DNLI $13.70
- Resistance Level
- CPRI $20.21
- DNLI $14.60
- Average True Range (ATR)
- CPRI 0.72
- DNLI 0.66
- MACD
- CPRI 0.05
- DNLI -0.05
- Stochastic Oscillator
- CPRI 71.88
- DNLI 36.42
About CPRI Capri Holdings Limited
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. Capri also owns a third brand, Versace, but has agreed to sell it to Prada. John Idol has served as Capri's CEO since 2003.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.